Special Issue "Novel Strategies and Technologies for the Development of Tumor-Specific Antibodies"
Deadline for manuscript submissions: 29 March 2024 | Viewed by 8096
In this Special Issue, we aim to compile a set of references and techniques that will support the generation of antibodies specific to tumor targeting and that fulfill appropriate therapeutic potential.
Antibody drug conjugates require target binders that support internalization, whereas antibody effector function requires sustained localization to the cell membrane to accomplish robust activity. Approaches for monoclonal antibodies and bispecific antibodies including immune cell engagers are also welcomed. Antibody characterization will also be addressed, and understanding the range of affinities (<0.1–50 nm), kinetics, domain/bin binding, among other properties, should be explained. How this is completed through in vivo and in vitro antibody discovery will serve as the backbone of this issue.
Dr. Alexander J. Bankovich
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antibody discovery
- display technologies
- effector function
- monoclonal antibodies
- bispecific antibodies